MSH6 gene

Last updated on: 01.05.2025

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The MSH6 gene (MSH6 stands for: MutS Homolog 6) is a protein-coding gene localized on chomosome 2p16.3. Transcript variants encoding different isoforms have been described. Associated signaling pathways include DNA repair pathways, the entire network and base excision repair. An important paralog of this gene is MSH2.

General informationThis section has been translated automatically.

The MSH6 gene encodes a member of the MutS family for the repair of DNA mismatches (see mismarch repair system below). In E. coli, the MutS protein helps to recognize mismatched nucleotides before they are repaired. In MutS homologs, there is a highly conserved region of about 150 aa, the so-called Walker A adenine nucleotide binding motif.

The encoded MSH6 protein forms a mismatch recognition complex in heterodimerization with the MSH2 protein, which acts as a bidirectional molecular switch that exchanges ADP and ATP when DNA mismatches are bound and separated.

PathophysiologyThis section has been translated automatically.

The encoded protein is a component of the post-replicative DNA mismatch repair system (MMR ).

MSH6 heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches to initiate DNA repair. When bound, MutS alpha bends the DNA helix and shields about 20 base pairs. It recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. After binding the mismatch, it forms a ternary complex with the heterodimer MutL alpha, which is thought to be responsible for controlling downstream MMR events, including strand discrimination, excision and resynthesis. ATP binding and hydrolysis play a central role in mismatch repair functions.

ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatching DNA provokes an ADP-->ATP exchange, resulting in a recognizable conformational change that transforms MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair.

MutS alpha may also play a role in the repair of homologous DNA recombinations.

Recruited to chromatin in G1 and early S phase via its PWWP domain that specifically binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early recruitment to chromatin to be replicated, allowing rapid identification of mismatch repair to initiate the DNA mismatch repair response.

ClinicThis section has been translated automatically.

Mutations in the MSH6 gene can be associated with various hereditary tumor entities, such as hereditary non-polyposis colorectal cancer, colorectal carcinoma and endometrial carcinoma. Other diseases associated with MSH6 include Lynch syndrome (see also Muir-Torre syndrome: In Muir-Torre syndrome, a rare autosomal dominant genodermatosis characterized by the occurrence of sebaceous gland neoplasia and/or keratoacanthomas and visceral malignancies, germline mutations are usually found in the DNA mismatch repair genes MSH2 and, although less frequently, in MLH1/Mahalingam M 2017).

LiteratureThis section has been translated automatically.

  1. Drummond JT et al. (1995) Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 268:1909-1912.
  2. Hempel C et al. (2025) Clinical and histopathological features of advanced cutaneous squamous cell carcinoma with varying responses to cemiplimab. J Dtsch Dermatol Ges 23:30-37.
  3. Botticelli A et al.(2021) Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Front. Immunol 12:705096.
  4. Gambichler T et al. (2021) Mismatch Repair Protein Expression and Microsatellite Instability in Cutaneous Squamous Cell Carcinoma. Curr Oncol 28:3316-3322.
  5. Mahalingam M (2017) MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots. Am J Dermatopathol 39:239-249.
  6. Rettig EM et al.(2015) Epidemiology of Head and Neck Cancer. Surg Oncol Clin N Am 24:379-396.
  7. Traver S et al. (2015) MCM9 Is Required for Mammalian DNA Mismatch Repair. Mol Cell 59:831-839.

Last updated on: 01.05.2025